Winter Capital has invested into Innova Partners, an operator of KidZania parks which provide children aged 4-14 with an opportunity to engage in real life role play experience which blends learning with entertainment. The company launched a park in Moscow in January 2016 and plans to expand its operations into the US, France and Canada. The first US park is expected to be launched in Dallas in 2018. KidZania, launched in 1999, has 24 locations in 19 countries, with another seven locations currently under development.

UCG, one of the leading manufacturers of shipbuilding cable across Russia and CIS, signed its first contract with an Indian customer. The company will supply power cables for 7 ships which are being constructed by Larsen & Toubro, one of the largest shipbuilders in India. This contract marks the beginning of UCG’s international expansion as the company plans to bring its expertise and solutions to markets outside of Russia and CIS.

In October 2016 the Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor) following the audit approved the issuance of a GMP certificate for Petrovax to manufacture the veterinary medicines AZOXIVET and Vetolaza. The Company has taken the lead as the 1^st Russian manufacturer of veterinary drugs that complies with the GMP standards approved in Russia.

More on petrovax.com

ZaOdno, a leading Russian dollar store operator, has announced the opening of its 100th store, which took place on October 29. Located in Mytishchi, Moscow region, the store occupies 350 square meters of floor space in Krasny Kit, a popular local mall. The store offers a wide range of everyday consumer products, general merchandise and seasonal items. The store’s opening marks another major milestone for the company, which is aiming to become an alternative to traditional retail stores. ZaOdno has been able to significantly broaden its customer base by delivering value on day-to-day purchases, and now has more than 1.5 million monthly visitors. It is expected that the retailer will continue to demonstrate significant growth rates through active expansion into the regions and further diversification of its product range.

More on zaodno.ru

The final round of startup competition “Pervaya Vysota” took place on 12 August at Digital October. The panel of judges (Alexey Bashkirov and Mikhail Tsyferov from Winter Capital Advisors, Dmitry Garanin and Evgeny Yakushkin from McKinsey and Julia Solovieva from Google) have selected 3 winners: Particle (talent search platform), Eristica (social betting mobile application) and Gavels (online auctions for residential real estate). Three winners will receive $75,000 each in exchange for a 10% stake in the company and half-year mentorship from Winter Capital Advisors and McKinsey professionals.

More info on pervaya-vysota.ru

Petrovax and Boehringer Ingelheim, a global pharmaceutical company, have signed an agreement to localize the full-cycle production of the most advanced thrombolytic drugs in Russia. The medicines are used for urgent treatment of infarctions and cerebrovascular accidents. The agreement effected as part of Russia's 2020 Pharmaceutical Industry Development Strategy (Pharma 2020). It is another step towards making essential lifesaving medicines more affordable in Russia.

For Boehringer Ingelheim this is the first localization project of its kind: by the end of 2019 Petrovax plans to complete the transfer of technology, quality controls and launch full-cycle production of thrombolytics at its production facility in the Moscow Region.

More on petrovax.com

DocPlanner, one of the largest European SaaS and lead generation platforms for healthcare services, announces a merger with Doctoralia, a Spain-based company operating in more than 20 countries. As a result of the merger the combined entity will become one of the leading online platforms in healthcare globally with presence in Europe, South America and Asia. The merger succeeded spring 2016 Series C round led by Target Global in which DocPlanner raised c. $20mn.

More on docplanner.com

Winter Capital and McKinsey have jointly launched startup competition “Pervaya Vysota”. Three winners will receive $75,000 each in exchange for a 10% stake in the company and half-year mentorship from Winter Capital Advisors and McKinsey professionals. The final will take place in Digital October on 12 August.

More on pervaya-vysota.ru

Following a government tender, Petrovax was selected as the sole supplier of the full volume of anti-flu vaccine for the 2016-2017 epidemiological season population of Kazakhstan eligible for free vaccination (including children from six months of age, pregnant women, healthcare workers and people aged 60 and over). This is a well-deserved recognition of the efficacy, safety and high quality standards of Petrovax’s product. Importantly, this is the first time Kazakhstan has purchased a Russian vaccine. Previously, anti-flu vaccines has only been supplied by countries outside of the former Soviet Union

More on petrovax.com

ZaOdno, one of the fastest-growing dollar store chains in Russia, has received additional financing from Winter Capital Partners. The company will use the majority of the proceeds to further expand its footprint in Central Russia. The remaining funds will be spent on improving logistics, merchandising and CRM capabilities.

More on zaodno.ru

On 19 February 2016, Petrovax, Sobhan Recombinant Protein and Arvin LTD signed a trilateral strategic cooperation agreement to localize the production of Grippol® Plus flu vaccine in Iran. The signing took place at Petrovax's production facility and was attended by representatives of the Deputy Health Minister and Head of the Food and Drug Organization of the Islamic Republic of Iran. As part of the cooperation, Petrovax will transfer its full-cycle production technology for the Russian Grippol® Plus flu vaccine to Sobhan Recombinant Protein (Iran) and train the Iranian company’s staff to replicate all production stages. Currently, Petrovax is the only Russian pharmaceutical company working to localize manufacturing of its innovative medicines in Iran.

More on petrovax.com